BMO Capital Starts Merck (MRK) at Market Perform

BMO Capital analyst Evan David Seigerman initiates coverage on Merck (NYSE: MRK) with a Market Perform rating and a price target of $91.00.

The analyst comments "We initiate coverage of Merck & Co with a Market Perform rating a $91 target price, based on our view: 1) Keytruda growth and continued success is fairly valued and priced into the stock; 2) A relatively thin late-stage pipeline (Acceleron was good, but not enough); 3) COVID-19 antiviral may not be as exciting for investors, given recent positive data from Pfizer; 4) Seagen partnership is interesting, but TNBC is rapidly becoming a competitive market."

For an analyst ratings summary and ratings history on Merck click here. For more ratings news on Merck click here.

Shares of Merck closed at $82.60 yesterday.

You May Also Be Interested In

• Merck (MRK) PT Raised to $155 at Scotiabank
• Truist Securities Downgrades Procept BioRobotics Corp (PRCT) to Hold
• General Mills (GIS) PT Lowered to $42 at Freedom Broker